Nancy McKinstry - 28 Apr 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
Director
Signature
/s/ Nancy McKinstry by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
28 Apr 2023
Net transactions value
$0
Form type
4
Filing time
02 May 2023, 19:57:00 UTC
Previous filing
17 Feb 2023
Next filing
16 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +1,816 +5.4% $0.000000 35,223 28 Apr 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +9,861 $0.000000 9,861 28 Apr 2023 Common Shares 9,861 $110.12 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2 Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.